B7-H3 targeted antibody-drug conjugate (risvutatug rezetecan) for recurrent Grade 4 glioma and brain metastases

A Phase 0/1 Clinical Trial With an Expansion Phase of GSK5764227, a B7-H3-Targeted Antibody-Drug Conjugate (ADC), in Patients With Recurrent Grade 4 Glioma and Patients With Brain Metastases

This study will try risvutatug rezetecan, a B7-H3 antibody-drug conjugate, in adults with recurrent Grade 4 glioma or brain metastases who are undergoing surgical resection.

Quick facts

• Phase: Early Phase 1
• Study type: Interventional
• Enrollment: 15 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: St. Joseph's Hospital and Medical Center, Phoenix (Academic / other)
• Drugs / interventions: Orlotamab, enoblituzumab, chemotherapy, prednisone
• Locations: 1 site (Phoenix, Arizona)
• Trial ID: NCT07268053 on ClinicalTrials.gov

What this trial studies

This open-label Phase 0/1 trial will enroll about 15 adults with recurrent WHO Grade 4 glioma or with brain metastases to receive risvutatug rezetecan, a B7-H3-targeted antibody-drug conjugate. The Phase 0 component (Arms A and B) uses perioperative dosing and pharmacokinetic (PK) sampling to determine the optimal time interval (OTI) for surgery that yields the highest payload concentration in tumor tissue. After the OTI is defined and DSMB review, Arm A Cohort 2 and Arm B will receive infusions at that schedule, and participants whose tumors show a positive PK response can enter a Phase 1 expansion to receive therapeutic dosing. Safety, PK, and tissue payload measurements will guide progression while participants without a positive PK signal will resume standard care.

Who should consider this trial

Good fit: Ideal candidates are adults (≥18) with recurrent WHO Grade 4 glioma after standard therapy or patients with brain metastases requiring resection, who have available tumor tissue, ECOG ≤2, adequate organ function, and controlled extracranial disease when applicable.

Not a fit: Patients whose tumors lack adequate B7-H3 target expression, who cannot undergo the required surgery and perioperative visits, or who have uncontrolled systemic disease or poor organ function are unlikely to benefit.

Why it matters

Potential benefit: If successful, this approach could deliver a tumor-targeted chemotherapy payload directly to B7-H3–expressing brain tumors, potentially improving local tumor control while limiting systemic toxicity.

How similar studies have performed: Antibody-drug conjugates and B7-H3 targeting have shown early promise in other cancers, but this approach remains experimental and unproven in recurrent glioblastoma and brain metastases.

Eligibility criteria

Inclusion Criteria:

* 1\. Diagnosed with: (a) GBM according to the 2021 WHO criteria, who have progressed on or following standard of care therapy, including maximal safe resection (biopsy allowed if resection was deemed unsafe) and concurrent chemoradiation; OR (b) Brain metastasis requiring surgical resection, whether treated or untreated, and must have well-controlled systemic disease or NED other than the brain metastases, in the opinion of the patient's primary oncologist.
* 2\. Has archival or biopsy brain tumor tissue available.
* 3\. Has measurable disease (preoperatively) defined as at least one contrast-enhancing lesion with two perpendicular measurements of at least 1 cm.
* 4\. Age ≥18 at time of consent.
* 5\. Has a performance status of ≤2 on the ECOG scale.
* 6\. Has adequate bone marrow and organ function as defined by the following laboratory values (as assessed by the local laboratory for eligibility):
* Adequate Bone Marrow Function: Absolute neutrophil count ≥1500/μL (≥1.5 x 109/L), Platelets (at time of surgery) ≥100,000/μL (≥100 x 109/L), Hemoglobin ≥9.0 g/dL or ≥5.6 mmol/L (Criteria must be met without erythropoietin dependency and without pRBC transfusion within prior 2 weeks.)
* Adequate Hepatic Function: Total Bilirubin ≤1.5x ULN (Participants with Gilbert's syndrome with a total bilirubin \>1.5x ULN and direct bilirubin ≤1.5x ULN will be permitted.), AST (SGOT) ≤2.5x institutional ULN, ALT (SGPT) ≤2.5x institutional ULN (Participants with liver metastases with ALT ≤5x ULN will be permitted.)
* Adequate Renal Function: eGFR ≥50 mL/min/1.73 m2 (Calculated as individualized eGFR using the CKD-EPI formula \[2021\]); If measured or calculated GFR (e.g., creatinine clearance; mGFR) is required or used: ≥60 mL/min
* Adequate Metabolic Function: Albumin ≥2.8 g/dL
* Adequate Coagulation: INR or PT and aPTT ≤1.5x ULN
* 7\. For females of childbearing potential: (a) Must have a confirmed negative serum pregnancy test (β-hCG) before starting study treatment (within 24 hours of first infusion); in rare cases where hCG is suspected to be elevated in the absence of pregnancy (e.g., due to a tumor producing hCG), an ultrasound must be performed to rule out possible pregnancy. (b) Must use a highly effective method of contraception (with a failure rate of \<1% per year and low user dependency) for at least 28 days prior to treatment, and agree to use such a method during study participation and for an additional 8 months after final study drug administration. (c) Agrees not to breastfeed starting at screening, during study participation, and for 8 months after final study drug administration. (d) Agrees not to donate eggs (ova, oocytes) for the purpose of reproduction starting at screening, during study participation, and for 8 months after final study drug administration.
* 8\. For females of non-childbearing potential, is no longer of childbearing potential due to surgical, chemical, or natural menopause.
* 9\. For males: (a) Agrees not to donate sperm starting at screening, during study participation, and for 5 months after final study drug administration. (b) Abstains from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agrees to remain abstinent starting at screening, during study participation, and for 5 months after final study drug administration; OR Must use a male condom and their female partner must use an additional highly effective method of contraception (with a failure rate of \<1% per year and low user dependency) starting at screening, during study participation, and for 5 months after final study drug administration.
* 10\. Agrees to adhere to Lifestyle Considerations throughout study duration.
* 11\. Able and willing to comply with scheduled visits, treatment plans, laboratory tests and other procedures.
* 12\. Understands the informed consent document and has voluntarily agreed to participate by giving written informed consent (personally or via legally authorized representative(s), and assent if applicable). Written informed consent for the protocol must be obtained prior to any screening procedures. If consent cannot be expressed in writing, it must be formally documented and witnessed, ideally via an independent trusted witness.

Exclusion Criteria:

* 1\. Evidence of leptomeningeal metastasis or spinal cord compression.
* 2\. Unable to undergo through MRI of the brain with IV contrast.
* 3\. Known active systemic bacterial infection (requiring IV antibiotics or fever \>38.5°C at time of initiating study treatment), fungal infection, or detectable viral infection (such as known human immunodeficiency virus positivity or with known active hepatitis B or C \[for example, hepatitis B surface antigen positive\] (screening of viral infection is not required for enrollment).
* 4\. Serious infections within 4 weeks prior to the first infusion of study drug, including but not limited to infectious complications, bacteremia, severe pneumonia treated with IV antibiotics for ≥2 weeks; active infections with therapeutic IV antibiotics within 2 weeks prior to the first infusion of study drug. (Individuals who are receiving or have received prophylactic antibiotics \[e.g., prophylaxis against urinary infections\] are allowed).
* 5\. Known other concurrent severe psychiatric and/or an uncontrolled medical condition that, in the Investigator's judgement, would cause unacceptable safety risks, contraindicate participation in the clinical study, or compromise compliance with the protocol.
* 6\. Have any unresolved toxicities from prior therapy greater than NCI-CTCAE v5 Grade 1 at the time of starting study treatment (exceptions include: alopecia, hearing loss, vitiligo, endocrinopathy managed with replacement therapy, Grade 2 neuropathy, and any chronic Grade 2 toxicities following discussion with the Principal Investigator).
* 7\. Has received treatment with any of the following:
* a. Orlotamab, enoblituzumab, I-Dxd, or otherB7-H3 targeted agents.
* b. Investigational agent within 4 weeks prior to the first infusion of study drug.
* c. Cytotoxic chemotherapy or anticancer drugs within 14 days prior to the first infusion of study drug.
* d. Monoclonal antibody within 28 days prior to the first infusion of study drug.
* e. Immunosuppressive agents within 30 days prior to the first infusion of study drug, or requires long-term (30 days or longer) glucocorticoid therapy. NOTE: A stable or reduced daily dose of 8 mg dexamethasone for management of GBM-related edema and its associated symptoms within 14 days prior to dosing is permitted; however, additional weekly CBC monitoring is required during concomitant administration of dexamethasone with GSK5764227, as outlined in the SoA (see section 1.3). NOTE: Low dose corticosteroids (prednisone ≤10 mg/day or equivalent) may be administered and use of inhaled or topical steroids and prophylactic corticosteroids for procedures are permitted.
* f. Strong/moderate inhibitors of CYP3A4, CYP2D6, P-gp, or BCRP, within 7 days prior to the first infusion of study drug; or need to continue treatment with these drugs (should be discontinued for at least 14 days prior to the first study infusion).
* g. Transfusion of blood products (including platelets or red blood cells) or administration of colony-stimulating factors (including G-CSF, granulocyte-macrophage colony-stimulating factor, or recombinant erythropoietin) with 14 days prior to enrollment.
* 8\. Major surgery within 4 weeks prior to the first infusion of study drug that, in the Investigator's judgement, would cause unacceptable safety risks.
* 9\. Clinically significant bleeding symptoms or significant bleeding tendency within 1 month prior to the first infusion of study drug.
* 10\. Allergy or hypersensitivity to any component of GSK5764227 (ADC, antibody, payload GSK5757810) or its excipients, history of severe allergies (e.g., anaphylactic shock), severe IRRs, or idiosyncrasy to recombinant humanized or mouse proteins.
* 11\. History of prior allogenic or autologous bone marrow transplant or other solid organ transplant.
* 12\. Has evidence of current ILD or pneumonitis, or history of ILD or noninfectious pneumonitis requiring high-dose glucocorticoids.
* 13\. History of moderate to severe lung disease.
* 14\. Has serious or poorly controlled hypertension including:
* a. History of hypertensive crisis.
* b. Hypertensive encephalopathy.
* c. Adjustment of antihypertensive medications due to poor blood pressure control within 2 weeks prior to the first infusion of study drug.
* d. Systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg during screening period.
* 15\. Has any of the following cardiac examination abnormalities:
* a. Evidence of current clinically significant arrhythmias or ECG abnormalities (e.g., complete left bundle branch block, third-degree AV block, second-degree AV block, PR interval \>250 msec).
* b. Risk factors of prolonged QTc or arrhythmia events, such as: heart failure, refractory hypokalemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death of any direct relative under 40 years old, or any concomitant medications that prolong the QT interval.
* c. Has QTc \>450 msec or \>480 msec for participants with bundle branch block (QTcF can be machine-calculated or manually over-read).
* d. Known reduced LVEF fraction \<50%.
* 16\. Has severe, uncontrolled or active cardiovascular disorders, including but not limited to:
* a. Myocardial infarction within 6 months prior to first infusion of study drug.
* b. Unstable angina within 6 months prior to the first infusion of study drug, not controlled by standard of care therapy.
* c. Congestive heart failure (NYHA Class III or IV congestive heart failure) within 6 months prior to the first infusion of study drug.
* d. Cerebrovascular accident or transient ischemic attack within 6 months prior to the first infusion of study drug.
* e. History of clinically significant (as determined by the Investigator) atrial arrhythmia, not controlled by standard of care therapy.
* f. History of clinically significant (as determined by the Investigator) ventricular arrhythmia, or occurrence of any clinically significant ventricular arrhythmia during screening.
* g. Serious arteriovenous thromboembolic events (such as deep vein thrombosis, pulmonary embolism, etc.) within 3 months prior to the first infusion of study drug (except for implantable venous port, catheter-related thrombosis, or superficial vein thrombosis, which are not considered "serious" thromboembolism).
* 17\. Known active infectious diseases requiring systemic treatment or known HIV. No active screening needed for active infectious diseases.
* 18\. Has documented presence HBsAg, hepatitis B core antibody (HbcAb), or hepatitis B surface antibody (HbsAb) (except for presence of HbsAb attributable to previous vaccination) at screening or within 3 months prior to the first infusion of study intervention.
* 19\. Has a positive HCV antibody test result at screening or within 3 months prior to the first infusion of study intervention. NOTE: Participants with a positive HCV antibody test result due to prior resolved disease can be enrolled if a confirmatory negative HCV RNA test is obtained and the participant otherwise meets entry criteria.
* 20\. Has a positive HCV RNA test result at screening or within 3 months prior to the first infusion of study intervention. NOTE: The HCV RNA test is optional, and participants with a negative HCV antibody test are not required to undergo HCV RNA testing as well.
* 21\. Has cirrhosis or current unstable livery or biliary disease (as determined by the Investigator) defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal/gastric varices, or persistent jaundice (individuals with stable non-cirrhotic chronic liver disease \[including Gilbert's syndrome or asymptomatic gallstones\] or hepatobiliary involvement of malignancy are permitted).
* 22\. History of autoimmune disease that has required systemic treatments in the 2 years prior to screening (individuals with prior history of autoimmune disease must be discussed with the Medical Monitor; replacement therapy is not considered a form of systemic therapy \[e.g., thyroid hormone for autoimmune thyroiditis or insulin is not exclusionary\]).
* 23\. Has any active renal condition (e.g., requirement for dialysis, or any other significant renal condition that could affect the participant's safety \[renal obstruction successfully managed by stenting is permitted\]).
* 24\. Is unable to adhere to the protocol-defined Schedule of Activities, including requirements for the Follow-up Period of the study, study procedures, restrictions, and requirements as determined by the Investigator.
* 25\. Known vaccination or hypersensitivity of any level within 4 weeks prior to the first infusion of study drug.
* 26\. Has received any live vaccine within 30 days prior to the first infusion of study drug.
* 27\. Is pregnant or breastfeeding.
* 28\. Has donated blood or blood products in excess of 500 mL (approximately 1 pint) within 1 month prior to first infusion of study intervention.

Where this trial is running

Phoenix, Arizona

• St. Joseph's Hospital and Medical Center — Phoenix, Arizona, United States (Recruiting)

Study contacts

• Principal investigator: Nader Sanai, MD — Ivy Brain Tumor Center
• Study coordinator: Phase 0 Navigator

Conditions Glioblastoma; Brain Metastasases; ADC; Antibody Drug Conjugate